Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Project leader/senior scientist at UniBern.
2 years in pharma industry.
8 years of research activity on the ECS
Full Professor at UniBern.
Collaboration with pharma industry.
10+ years of research activity on the ECS.
Updated: Nov 6, 2020
Synendos Therapeutics has been awarded of an Innosuisse Innovation Grant in collaboration with the group of Prof. J. Gertsch at the University of Bern. The funded project aims to characterize the new drug target of SERIs and to perform other explorative activities on biology and pharmacology of SERIs. The grant (ca. CHF 1m) has a duration of 3 years.
Synendos Series A Extension Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of...
Synendos Therapeutics Raises CHF 20 Million in Series A Financing.
Synendos won Venture Kick Stage III (CHF 100’000).
Comments